Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 10/20 | 0.51 |
| ▸ | ACE | P12821 | 3/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833863 | 0.97 | FKBP1A (0.54) | KLK7FKBP1AACEUCHL1MEN1 | |
| SCHEMBL5834113 | 0.83 | FKBP1A (0.59) | FKBP1AACE | |
| SCHEMBL7654989 | 0.82 | ACE (0.51) | FKBP1AACE | |
| SCHEMBL13086449 | 0.81 | KLK7 (0.53) | KLK7FKBP1AMEN1KMT2ANPC1 | |
| SCHEMBL5833963 | 0.81 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL5244800 | 0.81 | KLK7 (0.55) | KLK7FKBP1AUCHL1MEN1KMT2A | |
| SCHEMBL25338280 | 0.80 | KLK7 (0.57) | KLK7ACEUCHL1MEN1KMT2A | |
| SCHEMBL20595807 | 0.80 | KLK7 (0.57) | KLK7ACEUCHL1MEN1KMT2A | |
| SCHEMBL5834096 | 0.80 | FKBP1A (0.64) | FKBP1AACE | |
| SCHEMBL5833607 | 0.80 | FKBP1A (0.67) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056935-B2 | Rotamase enzyme activity inhibitors | GPI NIL HOLDINGS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | GLIAMED, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | FKBP14, FKBP1A, FKBP2 | KLK7 2704/4885FKBP1A 2/4885ACE 3581/4885 |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | KLK7 2310/4885FKBP1A 2/4885ACE 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.